company background image
LYRA

Lyra Therapeutics NasdaqGM:LYRA Stock Report

Last Price

US$2.98

Market Cap

US$94.8m

7D

-11.3%

1Y

-37.0%

Updated

08 Dec, 2022

Data

Company Financials +
LYRA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

LYRA Stock Overview

Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases.

Lyra Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Lyra Therapeutics
Historical stock prices
Current Share PriceUS$2.98
52 Week HighUS$8.18
52 Week LowUS$2.96
Beta-0.51
1 Month Change-33.93%
3 Month Change-51.54%
1 Year Change-37.00%
3 Year Changen/a
5 Year Changen/a
Change since IPO-83.94%

Recent News & Updates

Recent updates

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Mar 30
Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Invest In Growth?

Dec 14
Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Invest In Growth?

We Think Lyra Therapeutics (NASDAQ:LYRA) Can Afford To Drive Business Growth

Aug 28
We Think Lyra Therapeutics (NASDAQ:LYRA) Can Afford To Drive Business Growth

We're Not Very Worried About Lyra Therapeutics' (NASDAQ:LYRA) Cash Burn Rate

May 04
We're Not Very Worried About Lyra Therapeutics' (NASDAQ:LYRA) Cash Burn Rate

How Many Lyra Therapeutics, Inc. (NASDAQ:LYRA) Shares Do Institutions Own?

Mar 05
How Many Lyra Therapeutics, Inc. (NASDAQ:LYRA) Shares Do Institutions Own?

Companies Like Lyra Therapeutics (NASDAQ:LYRA) Are In A Position To Invest In Growth

Jan 11
Companies Like Lyra Therapeutics (NASDAQ:LYRA) Are In A Position To Invest In Growth

Shareholder Returns

LYRAUS PharmaceuticalsUS Market
7D-11.3%-0.3%-2.8%
1Y-37.0%14.1%-19.6%

Return vs Industry: LYRA underperformed the US Pharmaceuticals industry which returned 13.4% over the past year.

Return vs Market: LYRA underperformed the US Market which returned -21.2% over the past year.

Price Volatility

Is LYRA's price volatile compared to industry and market?
LYRA volatility
LYRA Average Weekly Movement9.4%
Pharmaceuticals Industry Average Movement11.0%
Market Average Movement7.4%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.3%

Stable Share Price: LYRA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: LYRA's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200559Maria Palasishttps://lyratherapeutics.com

Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It’s XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company’s product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps.

Lyra Therapeutics, Inc. Fundamentals Summary

How do Lyra Therapeutics's earnings and revenue compare to its market cap?
LYRA fundamental statistics
Market CapUS$94.84m
Earnings (TTM)-US$54.66m
Revenue (TTM)US$1.62m

58.4x

P/S Ratio

-1.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
LYRA income statement (TTM)
RevenueUS$1.62m
Cost of RevenueUS$38.19m
Gross Profit-US$36.56m
Other ExpensesUS$18.10m
Earnings-US$54.66m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.72
Gross Margin-2,252.93%
Net Profit Margin-3,367.84%
Debt/Equity Ratio0%

How did LYRA perform over the long term?

See historical performance and comparison